Across TCGA pan-cancer cohorts, STRN3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STRN3 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STRN3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STRN3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LUAD, LSCC, and GBM are the cancer types where STRN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.446	0.786	.008	25	view →
LSCC	OS	Median	All	0.931	0.798	.020	3	view →
GBM	DFS	Median	All	0.826	0.676	.020	3	view →
HNSC	DFS	Tertile	III,IV	1.000	0.897	.021	3	view →
PDAC	DFS	Median	III,IV	0.492	0.833	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: STRN3 tumor-vs-normal RNA expression · all STRN3 data types